Cardior Pharmaceuticals’ Post

Financing led by OrbiMed, Avoro Capital, and Samsara BioCapital, with additional investment from founding investor Medicxi Strengthens its leadership team with the appointments of industry veterans Rick Anderson as SVP Finance, Spencer Fisk as Chief Technical and Quality Officer, and Ling Zeng as General Counsel and EVP of Execution IND-enabling studies underway for first-in-class PD1/VEGFR2 bifunctional antibody [19 December 2024]: [London, UK/ Boston, US]: Ottimo Pharma (“Ottimo”), a priv... https://bit.ly/400Y7Zd #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb

🚀 Exciting News! SciGen Signs Strategic Partnership with Zuellig Pharma🚀 We are thrilled to officially announce a strategic partnership between SciGen and Zuellig Pharma, sealed September 10th, 2024. Zuellig Pharma’s vast distribution network and operational expertise will significantly bolster the reach of our key products—including Zometa, SciTropin A, and Lenalidomide—ensuring that these essential therapies arrive seamlessly where they are needed most . Alongside the improved distribution of existing products, we look forward to integrating future pipeline therapies into this robust network, reinforcing our commitment to delivering quality healthcare solutions across Singapore and beyond. This collaboration aligns perfectly with SciGen’s regional growth strategy. Our goal is to create a cohesive distribution network across Southeast Asia, ensuring that patients across multiple markets can access life-saving treatments efficiently and affordably. Key attendees in the signing ceremony at Zuellig Pharma office Scigen: Valery Yeo (CFO), Dr Shazli Khan (VP & Region Head, APAC) Zuellig Pharma: Tan Yan Ann (Managing Director), Dave Lai (Director) Their presence at this momentous event underscores the importance of this partnership and our shared vision for future growth and success. This is just the beginning of a new chapter for SciGen as we strengthen our footprint in Singapore and beyond. Together with Zuellig Pharma, we are confident in our ability to scale faster, serve better, and deliver on our promise of improving healthcare access across the region. #SciGen #ZuelligPharma #StrategicPartnership #HealthcareAccess #RegionalExpansion #Singapore #Vietnam #Thailand #Zometa #SciTropin #Lenalidomide

The life-science ecosystem of Wallonia (Southern Belgium) was showcased at the LSX World Congress by a panel of experts: Benoit Kenda, VP and Early Solution Partnering Head at UCB; Amel Tounsi, CEO of Bridge to Health; and Marc Foidart, Executive Chairman of EyeD Pharma. They offered a fresh perspective on the current investment and partnering landscapes within Europe, with a focus on Wallonia, Belgium. Find out more on the strategies and challenges involved in scaling up biotech innovations, the strengths and characteristics of Belgium and Wallonia's biotech ecosystem and the benefits and advantages to forming new partnerships within Belgium and the Walloon region. We are proud to have our life sciences ecosystem represented by such an impressive group of experts! UCB Bridge to Health (B2H) EyeD Pharma Wallonie Bruxelles International AWEX UK Wallonie-Bruxelles International - Research and Innovation Noshaq Pascale Delcomminette Bioxodes convEyXO EXO Biologics CorQuest MedTech Allyfe Gabi SmartCare Bio-Sourcing ODIX medical Amyl Therapeutics Bloomlife Inc neuroClues #biotech #innovation #investment #healthtech #healthcarerevolution #lifesciences

⏳ Only a few days left until #SwissBiotechDay2024! Join our team, Emmanuel Chereul and Natalia NIEMIR-DEVEAU, PhD, at the Swiss Biotech Association Day to learn more about Voxcan, your CRO specialized in non-invasive high-resolution imaging for non-clinical drug development. Don’t hesitate to contact them to arrange a meeting. We look forward to meeting you and exploring how Voxcan can support your projects! See you there! #SwissBiotechDay2024 #lifescience #nonclinical #CRO #partnering #drugdevelopment #infectiousdiseases #oncology #osteoarticulardiseases #drugdiscovery 

Europe's competitiveness in health and biotechnology is declining, as highlighted by the Draghi Report. To address this challenge, and in collaboration with the Association of the Pharmaceutical Industry in Norway (Legemiddelindustrien (LMI)) and Oslo Science City, we gathered leaders from across industry, government, and academia to discuss the pivotal role of Nordic countries in enhancing Europe's healthcare investment landscape. Among the proposed actions to take, were enhancing intellectual property to foster innovation, developing strategic partnerships to attract investment, and accelerating market access to ensure faster delivery of life-saving medicines. Additionally, the importance of cross-border and cross-sector collaboration was emphasized as a crucial factor in addressing today’s healthcare challenges. Thank you to everyone who contributed to great discussions and a memorable event; Peter Guenter, Hong Chow, Ole Petter Ottersen, Idar Kreutzer Cathrine M. Lofthus, Leif Rune Skymoen, Åslaug Helland, Bente Mikkelsen, Christine Wergeland Sørbye, Per Morten Sandset, Ole Alexander Opdalshei, Fredrik Schjesvold, Taher Hassen, Kristin Svanqvist, Siri Børø, Emilie Wolf Joner. #TeamMerck #AsOneForPatients

𝐓𝐫𝐚𝐝𝐞 𝐦𝐢𝐬𝐬𝐢𝐨𝐧 𝐭𝐨 𝐍𝐨𝐫𝐭𝐡 𝐂𝐚𝐫𝐨𝐥𝐢𝐧𝐚 🚀 Last week, our colleague Alejandro Rendón Uribe was on a trade mission to #NorthCarolina, between meetings, visits, and talks of great interest. North Carolina is one of the most important #biotechnology centers in the USA, home to a dense concentration of #biotech companies, pharmaceutical #research, academic institutions and #innovation centers. This mission opens interesting doors for #GalicianBiotechnology: Forging strategic partnerships between researchers and creating new services to improve our market-oriented R&D capabilities, strategies to help Galician biotech startups to smoothly enter the US market or a possible cooperation aimed at positioning #Galicia as a key player in the biotech sector are some of the milestones achieved. We were accompanied by 7 other entities from the Galician bioregion, in collaboration with the Axencia Galega de Innovación. Undoubtedly, it is an excellent opportunity to meet the leaders of the biotech sector in the area and explore opportunities for collaboration. The mission was clear: to position Galicia as a leader in the global biotech ecosystem, creating opportunities for talent, research, and business growth. #ProgramaFoexga #FEDER

📢 Major Milestone Alert! We are thrilled to announce that we have entered into a license agreement with EA Pharma, a subsidiary of Eisai Co., Ltd., for our lead compound, #evenamide. This partnership marks a significant #milestone for our company and the future of treatment for patients with (treatment-resistant) #schizophrenia. 🌟 Key Highlights of the Agreement: - EA Pharma will develop, manufacture and commercialize our innovative modulator of excessive glutamate, evenamide, in Japan and other designated Asian territories - Newron will receive up to a maximum total of €117m, structured as: >An upfront payment of €44m >Financial contributions for our upcoming Phase III study in H1 2025 >Milestone payments tied to regulatory and commercialization achievements In addition, Newron will receive tiered royalties of up to double-digit percentage of net sales for evenamide. 🌍 Together, with EA Pharma, we are working to bring evenamide to patients worldwide and explore further development opportunities in other territories. 👉 Stay tuned for updates on this exciting journey! #Newron #Innovation #Neuroscience #Partnerships

On January 14, 2025, the Korea Health Industry Development Institute (KHIDI) highlighted the success of its Boston C&D Incubation Office, which has supported domestic pharmaceutical and biotech companies in establishing a global presence since 2022. Key Highlights: 1. Global Impact: - Over three years, 35 companies benefited from office space, consulting, and networking opportunities. - Achievements include 5 company incorporations, 5 permits, and 3 technology exports. 2. Notable Success Stories: - Voronoi: Established a U.S. corporation and signed a $3.3 billion technology transfer agreement for autoimmune disease drugs. - Huons USA: Doubled exports of lidocaine anesthetics (from KRW 12.3 billion in 2022 to KRW 26.2 billion in 2023). Upcoming product launches in 2025 include multi-use lidocaine anesthetics. - Yuhan USA: Signed multiple venture fund agreements, collaborated with the University of Cincinnati, and is pursuing joint research and licensing agreements. - Abion: Received FDA approval for Phase 2 trials of a targeted cancer drug combination therapy in 2023. 3. Major Deals: - Orom Therapeutics secured a KRW 1.3 trillion license agreement with Vertex Corporation, and NexEye exported immunotherapy technology to Ono Pharmaceutical. 4. Supporting Innovation: - The C&D Incubation Office, located in Boston’s world-renowned bio cluster, offers companies subsidized rent, access to venture capital events, and opportunities to collaborate with global pharmaceutical leaders. Looking Ahead: Recruitment for 2025 will open in late January on the Bosanjin website. With expanding participation, KHIDI aims to reduce challenges for Korean companies entering global markets. For further details, you can read the full article here - https://lnkd.in/gZ7bPqtb For more updates on global biotech and pharmaceutical developments, follow Global Regulatory Insights. #BiotechInnovation #PharmaExpansion #BostonBioCluster #KoreanPharma #GlobalGrowth

🌟 New Partnership Announcement We are excited to share that we have entered into a license agreement with Myung In Pharm to develop, manufacture, and commercialize our lead compound, #evenamide, in #South #Korea. This collaboration combines #Newron's innovative approach with Myung In Pharm's clinical expertise and robust infrastructure in the CNS field. 💡 What this partnership brings: ▶️ Global Impact: Myung In Pharm will contribute 10% of patients to our pivotal Phase III trial (expected to begin in H1 2025) and share global development costs ▶️ Regional Expertise: Myung In Pharm will lead regulatory, marketing, and commercialization efforts in South Korea, ensuring evenamide reaches patients effectively ▶️ Shared Success: Newron will receive an upfront payment, development and regulatory milestone payments, and royalties on net sales This agreement builds on the momentum of recent milestones as we unlock new opportunities for evenamide in other Asian territories. We’re grateful for the trust and collaboration of our partners and look forward to jointly advance healthcare and deliver transformative therapies to patients. #Innovation #Neuroscience #Partnerships

💬 “Building a facility during COVID, while you are running another facility running 100% full, with a very high efficiency – the entire industry talks about this,” – Lars Petersen, President and CEO at FUJIFILM Diosynth Biotechnologies, Denmark.   💬 “We spent so many hours, there’s been so many people working on it, and soon we’ll be able to produce life-saving medicines. It’s incredible. And I feel honoured being a part of that whole journey,” – Christian Houborg, Senior Vice President, Fujifilm Diosynth Biotechnologies, Denmark.   Big changes start with bold visions and the dedication of people who bring them to life. We’re proud to celebrate the expansion of our Fujifilm Diosynth Biotechnologies facility in Hillerød, positioned to become one of the largest #CDMO sites in Europe.   With 6 new bioreactors, we’ve doubled our capacity to meet the growing global demand for critical therapies – helping our partners deliver life-changing treatments to patients faster and more efficiently. Behind this milestone is an incredible team whose passion, expertise, and commitment to innovation are shaping the future of how #biopharmaceuticals are manufactured. Looking forward to new achievements!   #Fujifilm #DiosynthBiotechnologies #biotechnologies #innovation